The press release<\/a> contained a few more
details about the changes than were released in the Power Point
presentation yesterday. Here is the text of those details.<\/div>
details about the changes than were released in the Power Point
presentation yesterday. Here is the text of those details.<\/div>
- “The 13 Board members appointed from
institutions eligible for funding from the stem cell agency, such as
those in the University of California <\/b>system, would no longer vote on
any grants brought before the Board but would instead abstain<\/li>“All members of the Board would
be able to participate in discussions on applications but only
patient advocates and independent members of the Board would be able
to vote on funding issues (members would continue to refrain from
any discussion of specific applications from their institutions)<\/div><\/li>“Patient Advocates would
continue to be members of the Grants Working Groups but would not
vote on individual applications<\/div><\/li>“Programmatic review, aimed at
balancing the agency’s portfolio, would take place at public Board
meetings where members have a chance to make changes to
recommendations from the Grants Working Group<\/div><\/li>“Industry involvement would
increase, where appropriate, on the Grants Working Group, and also
feature in a newly constituted Scientific Advisory Board; the
structure and membership of this group is still under discussion<\/div><\/li>“Appeals on applications not
recommended for funding will be handled by science staff who will
evaluate them, determine if they merit further review by the Grants
Working Group, and ultimately make recommendations to the Board.
Staff will also be allowed to advocate for additional grants not
recommended for funding by the Grants Working Group that they
believe should be considered in programmatic review<\/div><\/li>“The Chair and President would
share a division of responsibilities with the President supervising
all scientific operations and internal operational responsibilities.
In addition the Chief Financial Officer would report to the
President. The Chair would handle the ‘external affairs’ aspect
of the agency, things such as financial sustainability to raise
additional funds, state legislative relations, bond financing,
public communications etc.<\/div><\/li>“IOM recommendation on the
creation of a Scientific Advisory Board to provide counsel on such
issues as funding priorities and portfolio strategy will be
implemented by staff<\/div><\/li>“IOM recommendations on
Intellectual Property will be referred to the agency’s IP
subcommittee which will review and report back to the full board
with options and recommendations<\/div><\/li>“IOM recommendations on
Sustainability: Chair, working with the President, will develop a
plan to address this and present to the Board when ready<\/div><\/li><\/ul><\/div>Source:
http:\/\/feedproxy.google.com\/~r\/blogspot\/uqpFc\/~3\/MHSytXHG-zU\/stem-cell-agency-adds-fresh-details-to.html<\/a><\/p>","protected":false},"excerpt":{"rendered":"The California stem cell agency todayissued a press release touting “dramatic changes” at the agency in response to critical recommendations by the Institute of Medicine.The press release contained a few moredetails about the changes than were released in the Power … Continue reading